英国监管者批准Nanomerics进行新眼滴试验, 以治疗严重过敏症。 UK regulators approve Nanomerics' trial for new eye drop to treat severe allergies.

联合王国的MAHRA已经批准了Nanomerics的OC134临床试验,这是一个眼滴,旨在治疗中度至重度过敏结膜炎。 The UK's MHRA has approved Nanomerics' clinical trial for OC134, an eye drop aimed at treating moderate to severe allergic conjunctivitis. OC134使用该公司的分子信封技术(MET),这是一种非刺激性技术,可提高眼部穿透率。 OC134 uses the company's Molecular Envelope Technology (MET), a non-irritant technology that enhances ocular penetration. 这一批准标志着纳米学的重要一步,允许它们首次在人类中测试其精密医学技术。 This approval marks a significant step for Nanomerics, allowing them to test their precision medicine technology in humans for the first time.